Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy

Pharmacogenomics Journal

Volumn 9, Issue 1, 2009, Pages 61-70

  Wilkie, M J V ^a   Smith, G ^a   Day, R K ^a   Matthews, K ^a   Smith, D ^b   Blackwood, D ^b   Reid, I C ^c   Wolf, C R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; IMIPRAMINE; LOFEPRAMINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PHENELZINE; SERINE PROTEINASE OMI; SEROTONIN 1B RECEPTOR; SEROTONIN 5A RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DNA FLANKING REGION; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; PAROXETINE; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME;

EID: 59149086935     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500491     Document Type: Article

References (41)

1. Monsma Jr FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993; 43: 320-327.
2. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: A systematic review. Mol Psychiatry 2004; 9: 433-441.
3. Lesch KP, Balling U, Gross J, Strauss K, Wolozin BL, Murphy DL et al Organization of the human serotonin transporter gene. J Neural Transm Gen Sect 1994; 95: 157-162.
4. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215-219.
5. Yoshida K, Ito K, Sato K, Takahasti H, Kamata M, Higuchi H et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26 383-386.
6. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9: 879-889.
7. Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006; 6: 27-33.
8. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3 508-511.
9. Benedetti F, Colombo C, Serretti A, Lorenzi C, Pontiggia A, Barbini B et al. Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Biol Psychiatry 2003; 54: 687-692.
10. Benedetti F, Serretti A, Colombo C, Campori E, Barbini B, di Bella D et al. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry 1999; 156: 1450-1452.
11. Zanardi R, Benedetti F, Di Bella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105-107.
12. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Laltuada E et al. Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50: 323-330.
13. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003; 23: 563-567.
14. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003; 54: 879-883.
15. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM et al Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51: 723-732.
16. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587-590.
17. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115-1119.
18. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P et al Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression. Neurosci Lett 2001; 303: 119-122.
19. Ito K, Yoshida K, Sato K, Takahashi H, Kamata M, Higuchi H et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 2002; 111: 235-239.
20. Fiskerstrand CE, Lovejoy EA, Quinn JP. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 1999; 458: 171-174.
21. MacKenzie A, Quinn J. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci USA 1999; 96: 15251-15255.
22. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274 1527-1531.
23. Little KY, McLaughlin DP, Zhang L, Livermore CS, Dalack GW, McFinton PR et al. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry 1998; 155: 207-213.
24. Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983; 1: 214-216.
25. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J et al. The effect of paroxetine on 5-HT(2A) receptors in depression: An [(18)F]setoperone PET imaging study. Am J Psychiatry 2001; 158 78-85.
26. Cavus I, Duman RS. Influence of estradiol, stress, and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats. Biol Psychiatry 2003; 54: 59-69.
27. Duman RS. Synaptic plasticity and mood disorders. Mol Psychiatry 2002; 7(Suppl 1): S29-S34.
28. Vaidya VA, Siuciak JA, Du F, Duman RS. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience 1999; 89: 157-166.
29. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 1995; 15: 7539-7547.
30. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001; 50: 260-265.
31. Duman RS, Vaidya VA. Molecular and cellular actions of chronic electroconvulsive seizures. J Ect 1998; 14: 181-193.
32. Murphy Jr GM, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830-1835.
33. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R et al Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol 2002; 5: 27-35.
34. Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469-473.
35. Davis RL, Khoury MJ. A public health approach to pharmacogenomics and gene-based diagnostic tests. Pharmacogenomics 2006; 7: 331-337.
36. First MB. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version. American Psychiatric Press: Washington, DC, 1997.
37. First MB, McQueen LE, Pincus HA. DSM-IV Coding Update. American Psychiatric Association: Washington, DC, 1996.
38. Frances A, First MB, Pincus HA. DSM-IV Guidebook. American Psychiatric Press: Washington, DC, 1995.
39. Pincus HA, First M, Frances A, McQueen L. Reviewing DSM-IV. Am J Psychiatry 1996; 153: 850.
40. Sanders AR, Cao Q, Taylor J, Levin TE, Badner JA, Cravchik A et al Genetic diversity of the human serotonin receptor 1B (HTR1B) gene. Genomics 2001; 72: 1-14.
41. 267T) and clinical response to clozapine. Neuroreport 1999; 10: 1231-1233.